SEC Comment Letter 0000000000-24-007222 to KAZIA THERAPEUTICS LTD (KZIA) (CIK 0001075880) (KZIA)
KAZIA THERAPEUTICS LTD (KZIA) (CIK 0001075880)
Date: June 26, 2024 · CIK: 0001075880 · Accession: 0000000000-24-007222
AI Filing Summary & Sentiment
File numbers found in text: 333-280447
Letter
United States securities and exchange commission logo June 26, 2024 John Friend Chief Executive Officer Kazia Therapeutics Limited Three International Towers Level 24 300 Barangaroo Avenue Sydney, NSW, 2000, Australia Re:Kazia Therapeutics Limited Registration Statement on Form F-1 Filed June 25, 2024 File No. 333-280447 Dear John Friend: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Finnbarr D. Murphy, Esq.
Show Raw Text
United States securities and exchange commission logo
June 26, 2024
John Friend
Chief Executive Officer
Kazia Therapeutics Limited
Three International Towers Level 24
300 Barangaroo Avenue
Sydney, NSW, 2000, Australia
Re:Kazia Therapeutics Limited
Registration Statement on Form F-1
Filed June 25, 2024
File No. 333-280447
Dear John Friend:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Finnbarr D. Murphy, Esq.